The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
Open accessAbstract
BACKGROUND: A potential association between the use of angiotensin-receptor blockers (ARBs) and angiotensin-converting-enzyme (ACE) inhibitors and the risk of coronavirus disease 2019 (Covid-19) has not been well studied. METHODS: We carried out a population-based case-control study in the Lombardy region of Italy. A total of 6272 case patients in whom infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was confirmed between February 21 and March 11, 2020, were matched to 30,759 beneficiaries of the Regional Health Service (controls) according to sex, age, and municipality of residence. Information about the use of selected drugs and patients' clinical profiles was obtained from regional databases of health care use. Odds ratios and 95% confidence intervals for associations between drugs and infection, with adjustment for confounders, were estimated by means of logistic regression. RESULTS: Among both case patients and controls, the mean (±SD) age was 68±13 years, and 37% were women. The use of ACE inhibitors and ARBs was more common among case patients than among controls, as was the use of other antihypertensive and non-antihypertensive drugs, and case patients had a worse clinical profile. Use of ARBs or ACE inhibitors did not show any association with Covid-19 among case patients overall (adjusted odds ratio, 0.95 [95% confidence interval {CI}, 0.86 to 1.05] for ARBs and 0.96 [95% CI, 0.87 to 1.07] for ACE inhibitors) or among patients who had a severe or fatal course of the disease (adjusted odds ratio, 0.83 [95% CI, 0.63 to 1.10] for ARBs and 0.91 [95% CI, 0.69 to 1.21] for ACE inhibitors), and no association between these variables was found according to sex. CONCLUSIONS: In this large, population-based study, the use of ACE inhibitors and ARBs was more frequent among patients with Covid-19 than among controls because of their higher prevalence of cardiovascular disease. However, there was no evidence that ACE inhibitors or ARBs affected the risk of COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K., Bleicker, T., Brünink, S., Schneider, J., Schmidt, M. L., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.3.2000045 · Cited by 7,344
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China
Shi, S., Qin, M., Shen, B., Cai, Y., Liu, T., Yang, F., Gong, W., Liu, X., Liang, J., Zhao, Q., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0950 · Cited by 4,349
Cardiovascular implications of fatal outcomes of patients with Coronavirus Disease 2019 (COVID-19)
Guo, T., Fan, Y., Chen, M., Wu, X., Zhang, L., He, T., Wang, H., Wan, J., Wang, X., & Lu, Z. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1017 · Cited by 4,194
Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy
Onder, G., Rezza, G., & Brusaferro, S. (2020) · JAMA · doi:10.1001/jama.2020.4683 · Cited by 4,171
COVID-19 and the cardiovascular system
Zheng, Y.-Y., Ma, Y.-T., Zhang, J.-Y., & Xie, X. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0360-5 · Cited by 2,970
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
Fang, L., Karakiulakis, G., & Roth, M. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30116-8 · Cited by 2,911
Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101
Physiology of Local Renin-Angiotensin Systems
Paul, M., Poyan Mehr, A., & Kreutz, R. (2006) · Physiological Reviews · doi:10.1152/physrev.00036.2005 · Cited by 1,739
Ferrario, C. M., Jessup, J., Chappell, M. C., Averill, D. B., Brosnihan, K. B., Tallant, E. A., Diz, D. I., & Gallagher, P. E. (2005) · Circulation · doi:10.1161/circulationaha.104.510461 · Cited by 1,565
Halliday, B. P., Wassall, R., Lota, A. S., Khalique, Z., Gregson, J., Newsome, S., Jackson, R., Rahneva, T., Wage, R., Smith, G., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32484-x · Cited by 655
Danser, A. H. J., Epstein, M., & Batlle, D. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15082 · Cited by 457
SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19?
Kuster, G. M., Pfister, O., Burkard, T., Zhou, Q., Twerenbold, R., Haaf, P., Widmer, A. F., & Osswald, S. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa235 · Cited by 395
Patel, A. B., & Verma, A. (2020) · JAMA · doi:10.1001/jama.2020.4812 · Cited by 378
Kreutz, R., Algharably, E. A. E.-H., Azizi, M., Dobrowolski, P., Guzik, T., Januszewicz, A., Persu, A., Prejbisz, A., Riemer, T. G., Wang, J.-G., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa097 · Cited by 357
Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19
Bozkurt, B., Kovacs, R., & Harrington, B. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.04.013 · Cited by 355
Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?
Esler, M., & Esler, D. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002450 · Cited by 296
Generating Evidence From Computerized Healthcare Utilization Databases
Corrao, G., & Mancia, G. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04858 · Cited by 114
Self-citationRea, F., Corrao, G., Merlino, L. G., & Mancia, G. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy420 · Cited by 106
Self-citationPharmacologic modulation of ACE2 expression
Soler, M. J., Barrios, C., Oliva, R., & BATLLE, D. C. (2008) · Current Hypertension Reports · doi:10.1007/s11906-008-0076-0 · Cited by 88
Vardeny, O., Claggett, B. L., Kachadourian, J., Pearson, S. M., Desai, A. S., Packer, M., Rouleau, J. L., Zile, M. R., Swedberg, K. B., Lefkowitz, M. P., et al. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004745 · Cited by 84
Adherence With Antihypertensive Drug Therapy and the Risk of Heart Failure in Clinical Practice
Corrao, G., Rea, F., Ghirardi, A., Soranna, D., Merlino, L. G., & Mancia, G. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05463 · Cited by 82
Self-citationHirakawa, Y., Arima, H., Webster, R. J., Zoungas, S., Li, Q., Harrap, S. B., Lisheng, L., Hamet, P., Mancia, G., Poulter, N. R., et al. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000841 · Cited by 45
Self-citationLiu, C., Shau, W., Wu, C., & Lai, M. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e328357a87a · Cited by 35
Rea, F., Corrao, G., Ludergnani, M., Cajazzo, L., & Merlino, L. G. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.08.009 · Cited by 21
Self-citation
Cited by
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Self-citationExtrapulmonary manifestations of COVID-19
Gupta, A., Madhavan, M. V., Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T. S., Bikdeli, B., Ahluwalia, N., Ausiello, J. C., Wan, E. Y., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0968-3 · Cited by 3,185
Mechanisms of SARS-CoV-2 entry into cells
Jackson, C. B., Farzan, M., Chen, B., & Choe, H. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00418-x · Cited by 3,022
Zhou, B., Perel, P., Mensah, G. A., & Ezzati, M. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00559-8 · Cited by 1,521
Metadata
- Authors
- Mancia, G., Rea, F., Ludergnani, M., Apolone, G., & Corrao, G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-06-18
- Volume
- 382
- Issue
- 25
- Pages
- 2431-2440
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3023640683
- Cited by
- 1,073
- References
- 29
- FWCI
- 30.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.